TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29402358
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without early mobilization)
Study: 24701731
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow (FGF) rate at 0.5 L x min(‐1)
Study: 24701731
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow (FGF) rate at 1 L x min(‐1)
Study: 24701731
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow (FGF) rate at 2 L x min(‐1)
Study: 16878408
Drug: Chemo-radiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-radiation therapy
Study: 3926729
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion added to parenteral feed
Study: 3926729
Drug: Without insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Without insulin
Study: 30640244
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with bupivacaine and levobupivacaine 2 mg/kg and adrenaline 0.5 mg
Study: 26011733
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose praziquantel (40 mg/kg body weight)
Study: 26011733
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose praziquantel (40 mg/kg body weight, second dose 2 weeks later)
Study: 19029226
Drug: r-metHuLeptin treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHuLeptin treatment
Study: 15326246
Drug: Albuterol (sustained-release,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (sustained-release, 8 mg BID)
Study: 9401646
Drug: Exogenous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous GLP-1 [7-36 amide] infusion (0.4, 0.8 pmol kg-1 min-1)
Study: 9401646
Drug: Liquid mixed
Normalized name: ENSURE CLEAR LIQUID MIXED BERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid mixed meal (50 g sucrose in 400 ml 8% amino acid)
Study: 9401646
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control for GLP-1 infusion)
Study: 8221563
Drug: GM-CSF (5.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF (5.5 micrograms/kg protein dosage per day from day-6 to day-4 before chemotherapy)
Study: 8221563
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (without GM-CSF)
Study: 3304564
Drug: Methohexital (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (0.1 mg/kg/min continuous infusion)
Study: 3304564
Drug: Thiopental (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopental (5 mg/kg I.V. bolus)
Study: 20118151
Drug: Bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin monotherapy with VCD
Study: 18298700
Drug: Topiramate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (all doses combined)
Study: 10824049
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2.5 mg amlodipine and 5 mg lisinopril
Study: 10824049
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg and 5 mg) and Lisinopril (5 mg and 10 mg)
Study: 1378112
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR (50-100 mg once daily)
Study: 1378112
Drug: Conventional nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional nifedipine tablet (20-40 mg twice daily)
Study: 1378112
Drug: Conventional nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional nifedipine tablet
Study: 7041665
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg single dose in adults
Study: 7041665
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg per day for 3 consecutive days
Study: 7041665
Drug: Albendazole 200
Normalized name: albendazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 200 mg in children
Study: 31788029
Drug: Autologous skin
Normalized name: Autologous skin culture
DrugBank: Autologous skin culture (DB18524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous skin cell suspension (ReCell®)
Study: 25132247
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1 μg/kg followed by 0.2 μg/kg per h infusion)
Study: 15871360
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of brimonidine tartrate
Study: 11316161
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of interferon alpha‐2b and ribavirin (1000‐1200 mg/day) for 12 months
Study: 11316161
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU of interferon alpha‐2b and ribavirin (1000‐1200 mg/day) for 12 months
Study: 15374128
Drug: Controlled-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release melatonin (2 mg per night)
Study: 8193492
Drug: Alfentanil 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 20 micrograms/kg plus suxamethonium 1.5 mg/kg
Study: 9337490
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for depression (CBT-D)
Study: 11495176
Drug: Standard cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioral smoking cessation treatment (ST)
Study: 20412090
Drug: 5% vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% vitamin K cream
Study: 17272735
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram for 12 weeks
Study: 16210859
Drug: Desloratadine (DL)
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine (DL) 20 mg daily for 4 weeks
Study: 12014839
Drug: CoQ10 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 treatment in senescent rat hearts
Study: 12014839
Drug: Oral CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral CoQ10 therapy for 2 weeks pre-operatively
Study: 30166260
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi exercise program (3 times weekly for 3 months)
Study: 28235533
Drug: Ropivacaine 0.1%
Normalized name: ROPivacaine 0.1% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.1% with fentanyl 2.5 μg/mL
Study: 28235533
Drug: Bupivacaine 0.0625%
Normalized name: BUPIVACAINE 0.0625%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.0625% with fentanyl 2.5 μg/mL
Study: 28128983
Drug: EPA-enriched liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-enriched liquid supplement (2 g/day)
Study: 28128983
Drug: Powdered supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered supplement without EPA
Study: 16787192
Drug: Prostaglandin E‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin E‐1 (PGE‐1) treatment
Study: 15043177
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a standard sliding-scale insulin regimen and routine diabetes medications
Study: 15043177
Drug: Routine diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine diabetes medications (control)
Study: 9279425
Drug: Treatment involving
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment involving observation over a nine-week period, with three weeks of treatment focused on lexical development and verb constructions.
Study: 29948858
Drug: Adaptive servo-ventilation
Normalized name: Servo Stat Bac
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive servo-ventilation (ASV) on top of standard therapy for acute heart failure
Study: 23696211
Drug: Ultrasound-guided needling
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided needling and lavage (barbotage) combined with a US-guided corticosteroid injection in the subacromial bursa (group 1)
Study: 23696211
Drug: Subacromial corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial corticosteroid injection (SAI) alone (group 2)
Study: 17469198
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH), 1 mg every second day for 6 months followed by alternating daily injections of 1 mg and 0.5 mg for another 6 months
Study: 19195665
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (r-hGH)
Study: 8965780
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate added to the drug regimen
Study: 1738927
Drug: Antibody-treated patients
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-treated patients
Study: 1738927
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not receiving antibody prophylaxis
Study: 6423328
Drug: mannitol 0.5
Normalized name: MANNITOL 0.54%/SORBITOL 2.7% IRRG SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: mannitol 0.5 g/kg body weight
Study: 27913032
Drug: Fluticasone aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone aerosol combined with theophylline tablets
Study: 27913032
Drug: Salmeterol/fluticasone aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone aerosol combined with placebo tablets
Study: 20064514
Drug: Once-daily dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily dosing of delayed-release mesalamine (1.6-2.4 g/day)
Study: 20064514
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing of delayed-release mesalamine (1.6-2.4 g/day)
Study: 8725181
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl 200 mg/day
Study: 8725181
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl 600 mg/day
Study: 8725181
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (Premarin, 0.625 mg/day)
Study: 26663669
Drug: Nightly 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly 50 mg sildenafil citrate
Study: 24642191
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone 5mg plus acetaminophen 325mg
Study: 18164965
Drug: GG genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GG genotype of VEGF-1154 (A/G)
Study: 9046850
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine at 10 ml/hr
Study: 9046850
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine at 10 ml/hr
Study: 2058816
Drug: Bricanyl Turbuhaler
Normalized name: terbutaline sulfate Oral Solution [Bricanyl]
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bricanyl Turbuhaler (0.5 mg terbutaline sulphate)
Study: 2058816
Drug: Ventolin Rotahaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventolin Rotahaler (0.4 mg salbutamol)
Study: 6575836
Drug: Cranial irradiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial irradiation plus 5 doses of intrathecal methotrexate (i.t. MTX)
Study: 25785701
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) treatment breathing 100% oxygen under 2.5 ATA for 60 minutes
Study: 24351352
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone preoperatively
Study: 21368716
Drug: GTS-21 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTS-21 (150 mg, orally three times per day for 3 days)
Study: 19636035
Drug: Drugs flagged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs flagged as potentially inappropriate by Beers criteria
Study: 19636035
Drug: Drugs flagged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs flagged as potentially inappropriate by Zhan criteria
Study: 19636035
Drug: Drugs identified
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drugs identified as problematic by the physician-pharmacist team
Study: 19636035
Drug: Concordance between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concordance between drugs-to-avoid criteria and expert assessments
Study: 15113949
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (330 mL/d for 2 weeks)
Study: 15113949
Drug: Carrot juice
Normalized name: carrot juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice (330 mL/d for 2 weeks)
Study: 31401165
Drug: Enalapril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5-10 mg/day)
Study: 8089635
Drug: Control (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alpha methyldopa 500 mg/day)
Study: 3316575
Drug: Cyclosporine alone
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine alone (15 to 17 mg/kg)
Study: 3316575
Drug: Cyclosporine plus
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine plus prednisolone (0.3 mg/kg/d)
Study: 3316575
Drug: Cyclosporine alone
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine alone (8 to 10 mg/kg/d)
Study: 31858338
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil diolamine
Study: 25967607
Drug: Hedan Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hedan Tablet 4.38 g/day
Study: 23329206
Drug: Sumatriptan infusion
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan infusion
Study: 17189470
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine treatment after acid-etching
Study: 15041116
Drug: Tadalafil with
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil with tadalafil dosing instructions
Study: 11468015
Drug: diclofenac-K 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac-K 12.5 mg
Study: 11468015
Drug: ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen 200 mg
Study: 11468015
Drug: aspirin 500
Normalized name: aspirin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin 500 mg
Study: 2365538
Drug: SR nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR nicardipine (40 mg twice a day)
Study: 2698934
Drug: Chlorthalidone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (25 mg once a day)
Study: 227072
Drug: Tiapride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapride (300 mg/day, IM route)
Study: 23979365
Drug: IV ART-123
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ART-123 (0.06 mg/kg/d) for 6 days
Study: 9635652
Drug: Air insufflation
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air insufflation technique (500 mL of air instilled into the stomach)
Study: 8171951
Drug: Fentanyl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1 mg prior to surgery, 0.05 mg every 30 min during surgery)
Study: 8171951
Drug: Alfentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (0.5 mg prior to surgery, 0.25 mg every 15 min during surgery)
Study: 3335192
Drug: Kreon, three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kreon, three times six capsules daily
Study: 3335192
Drug: Panzytrat 20.000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panzytrat 20.000, three times three capsules daily
Study: 30633580
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplements (ONS)
Study: 29789878
Drug: Full-dose nut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose nut diet (75 g/day mixed nuts)
Study: 29789878
Drug: Full-dose muffin
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose muffin diet (three whole-wheat muffins, 188 g/day)
Study: 29789878
Drug: Half-dose nut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose nut diet (half portions of both nuts and muffins)
Study: 29789878
Drug: Full-dose nut
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose nut diet
Study: 27389118
Drug: Ultrasound-guided genicular
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided genicular nerve pulsed RF treatment
Study: 21417811
Drug: Ozone therapy
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone therapy (major autohemotherapy, minor autohemotherapy, and rectal ozone insufflation)
Study: 21417811
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (silymarin and/or multivitamins)
Study: 14599834
Drug: Percutaneous release
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous release with steroid injection
Study: 30915366
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection alone
Study: 7829015
Drug: Cyclical antibiotics
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical antibiotics (ampicillin, metronidazole, ciprofloxacin) and ursodeoxycholic acid
Study: 7829015
Drug: Cyclical antibiotics
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical antibiotics and ursodeoxycholic acid
Study: 29141460
Drug: Metformin up-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin up-titration (1,500-2,250 mg/day)
Study: 29141460
Drug: Control (maintaining
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (maintaining low-dose metformin)
Study: 29141460
Drug: Metformin up-titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin up-titration
Study: 26515419
Drug: Extended-release niacin
Normalized name: niacin Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release niacin (ERN; 1-2 g/d)
Study: 20184222
Drug: Fluoxetine (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (reference formulation)
Study: 18383987
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (diet with > 30 g of fiber and < 16 g of saturated fat, exercise 5-6 days/week, strength training 3 days/week, stress management 10-20 minutes daily)
Study: 16723101
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (IMN) 40 mg with dinoprostone 3 mg
Study: 16723101
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with dinoprostone 3 mg
Study: 10921762
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via Diskus (cumulative doses of 200, 400, 800, 1600, and 3200 microg)
Study: 10921762
Drug: Salbutamol via
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol via Turbuhaler (cumulative doses of 200, 400, 800, 1600, and 3200 microg)
Study: 8833682
Drug: Antidepressant-treated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant-treated group
Study: 8833682
Drug: Referent group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referent group without antidepressant treatment
Study: 1452374
Drug: Diltiazem (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (30 mg three times a day)
Study: 6483162
Drug: Doxefazepam 10
Normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxefazepam 10 mg
Study: 6483162
Drug: Doxefazepam 20
Normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxefazepam 20 mg
Study: 6483162
Drug: Doxefazepam 40
Normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxefazepam 40 mg
Study: 6483162
Drug: Doxefazepam 10
Normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxefazepam 10 mg (2-week administration)
Study: 6483162
Drug: Doxefazepam 10
Normalized name: doxefazepam
DrugBank: Doxefazepam (DB13837)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxefazepam 10 mg (self-administered at home)